We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Amersham's mystery suitor

8 October 2003 By Hugo Dixon

Broadlybased health groups such as Roche and Johnson & Johnson look the most likely acquirers for the £4.6bn UK medical group. Amersham could be attractive because it is market leader in two of its businesses, enjoys high barriers to entry and isn t that expensive.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.